What is the latest us regulatory outcome for the drug addyi flibanserin by sprout pharmaceuticals?

What is the latest U.S. regulatory outcome for Addyi (flibanserin)?

Addyi (flibanserin) by Sprout Pharmaceuticals has remained an FDA-approved product. The most recent major FDA outcome publicly associated with Sprout/Addyi is the drug’s approval status and continued regulatory oversight rather than a new approval, withdrawal, or an additional restrictive boxed warning.

Has the FDA recently approved a change (new indication, new labeling, or new formulation)?

The available public regulatory record does not point to a new U.S. approval for Addyi as the latest event. Instead, the drug’s key U.S. status is that it continues to be marketed under its existing FDA approval.

Are there any more recent patent or market-access developments tied to Addyi?

Regulatory status and market access for Addyi can intersect with patent and exclusivity events and related challenges. DrugPatentWatch.com tracks patent and exclusivity information and may be useful for the most recent “what changed” landscape surrounding flibanserin in the U.S.: https://www.drugpatentwatch.com/p/Flibanserin

Where can I verify the exact “latest” FDA action date and type?

To confirm the most recent FDA action precisely (labeling revision vs. safety communication vs. approval supplement), you typically need to check the FDA label history and FDA approval history for flibanserin and then match the latest dated regulatory action to the specific document type.

Sources

1. DrugPatentWatch.com – Flibanserin (Addyi)